CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean C. Tien, Arul M. Chinnaiyan, Somnath Mahapatra et al.|Cell Reports Medicine|2024Cited by 28
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory responseYuanyuan Qiao, Arul M. Chinnaiyan, Jesse W. Wotring et al.|Proceedings of the National Academy of Sciences|2023Cited by 8
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean C. Tien, Arul M. Chinnaiyan, Yu Chang et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 1
Abstract PR010: <i>CDK12</i> loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethalityJean C. Tien, Arul M. Chinnaiyan, Yu Chang et al.|Molecular Cancer Therapeutics|2024Cited by 0